Glutamate-based Therapies for Psychiatric Disorders
Both metabotropic and ionotropic glutamate receptors present attractive “druggable” targets in treating disorders of the central nervous system. There has been a dramatic shift in the focus of glutamate-based therapies away from neurologic disorders such as stroke and traumatic brain injury to the t...
Wedi'i Gadw mewn:
| Awdur Corfforaethol: | |
|---|---|
| Awduron Eraill: | |
| Fformat: | Electronig eLyfr |
| Iaith: | English |
| Cyhoeddwyd: |
Basel :
Birkhäuser Basel : Imprint: Birkhäuser,
2010.
|
| Rhifyn: | 1st ed. 2010. |
| Cyfres: | Milestones in Drug Therapy,
|
| Pynciau: | |
| Mynediad Ar-lein: | https://doi.org/10.1007/978-3-0346-0241-9 |
| Tagiau: |
Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!
|
Tabl Cynhwysion:
- N-Methyl-d-Aspartate (NMDA) Antagonists for the Treatment of Depression
- Ionic Glutamate Modulators in Depression (Zinc, Magnesium)
- Positive Allosteric Modulation of AMPA Receptors: A Novel Potential Antidepressant Therapy
- Glutamatergic Modulators for the Treatment of Major Depressive Disorder: Metabotropic Glutamate Receptors
- Positive Modulation of AMPA Receptors as a Broad-Spectrum Strategy for Treating Neuropsychiatric Disorders
- Activation of Group II Metabotropic Glutamate Receptors (mGluR2 and mGluR3) as a Novel Approach for Treatment of Schizophrenia
- mGluR1 Negative Allosteric Modulators: An Alternative Metabotropic Approach for the Treatment of Schizophrenia
- Metabotropic Glutamate Receptors as Targets for the Treatment of Drug and Alcohol Dependence
- Metabotropic Approaches to Anxiety.